Premier ingredient Sytrinol to be available for growing practitioner market
CHICAGO, IL – SourceOne Global Partners has announced it has signed an exclusive agreement with Douglas Laboratories of Pittsburgh, PA, to market Sytrinol, SourceOne’s proprietary, patented cardiovascular support compound, to the lucrative practitioner market.
“The increased awareness, acceptance and utilization of scientifically sound dietary supplements and nutraceuticals by the medical community has greatly expanded opportunities for suppliers such as SourceOne to ensure patients receive exceptional support with natural-based compounds,” observes Jesse R. Lopez, founder and CEO of SourceOne Global Partners. “Medical professionals are highly discerning and often reluctant to recommend, much less sell, nutritional compounds and dietary supplements. But, when they believe in a supplement enough to sell it to their patients, this bodes well for the credibility of the entire dietary supplement industry.”
Douglas Laboratories, Lopez adds, is the leading supplier to the practitioner market nationwide with strong distribution in Canada, Europe, Japan and Korea as well. Its exceptional reach and impeccable reputation for marketing high-quality, safe and efficacious supplements backed by solid research has earned Douglas Laboratories a loyal and wide base of health care professionals.
Douglas Lioon, CEO of Douglas Laboratories, comments, “We only work with those compounds that have elegant scientific support. After all, a doctor’s entire reputation is on the line if he or she offers a substandard supplement. Our standards are high, and Sytrinol is just what the doctor ordered, so to speak.”
Sytrinol, a patented proprietary formula derived from citrus and palm fruit extracts, is composed of polymethoxylated flavones and tocotrienols. Multiple clinical trials have demonstrated that Sytrinol acts synergistically to significantly reduce total cholesterol, LDL cholesterol and triglycerides by 25%, 22% and 28%, respectively. Additionally, Sytrinol is a powerful antioxidant with numerous heart health benefits including playing a significant role as an anti-inflammatory. Unlike other cholesterol-targeted supplements, Sytrinol is not diet specific and has no known side effects.* SourceOne owns the exclusive worldwide license for the intellectual property associated with Sytrinol.
For more than 50 years, Douglas Laboratories has been the professional’s choice for tens of thousands of health care professionals. The company’s modern, climate-controlled facilities include more than 150,000 square feet of world-class manufacturing, three in-house laboratories and packaging and distribution capabilities. Custom formulating and manufacturing versatility are handled by its dedicated staff of nutritional and manufacturing experts.
SourceOne Global Partners represents a new breed of ingredient supplier, partnering with manufacturing clients to introduce powerfully branded, science-driven products to market with a unique product positioning and compelling consumer presence. SourceOne was conceived as a company whose core competence is to integrate legitimate science with strong trade and consumer branding. SourceOne Global Partners cultivates relationships with leading suppliers worldwide to source and offer patented ingredients supported by proprietary science as part of a turnkey marketing program that dramatically increases the odds for marketing success.
*Sytrinol: A new cholesterol-lowering product. Najla Guthrie & Elzbieta Kurowska, Proc. Int. Conference on Nutraceuticals and Functional Foods, San Diego, CA, November, 2002